The business of developing antibacterials

Nature Biotechnology

Volumn 24, Issue 12, 2006, Pages 1521-1528

  Fox, Jeffrey L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; INDUSTRIAL ECONOMICS; MARKETING;

ANTIBACTERIALS;

ANTIBIOTICS;

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; ACH 702; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; API 1252; AR 709; AZITHROMYCIN; CEFTOBIPROLE; CEM 101; CEM 102; CERAGENIN; CETHROMYCIN; CIPROFLOXACIN; CPI 226; DAPTOMYCIN; DC 159A; DX 619; EA 230; EPICREAM; ERYTHROMYCIN; FAS 20013; GEMIFLOXACIN; ICLAPRIM; LINEZOLID; LMP 102; MACROLIDE; MBX 500; MK 2764; MP 601; MX 2401; MX 594A; MX 594AN; NXK 103; NXK 104; OPT 90; OXAQUIN; OXAZOLIDINONE DERIVATIVE; P 113D; PEXIGANAN ACETATE; PLECTASIN; PTK 0796; PYRIDINE DERIVATIVE; PZ 601; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REP 8839; RIFALAZIL; RX 01; TELAVANCIN; UNINDEXED DRUG; VANCOMYCIN; VX 692; VX 883;

ACNE; ARTERY DISEASE; ASIA; ATOPIC DERMATITIS; BACTEREMIA; BACTERIAL INFECTION; BIOLOGICAL WARFARE; BIOTECHNOLOGY; CANCER THERAPY; CATHETER INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; DIABETIC FOOT; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC ASPECT; ETHNIC AND RACIAL GROUPS; EUROPE; FUNDING; GOVERNMENT; GRAM POSITIVE BACTERIUM; HIGH THROUGHPUT SCREENING; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROGRAM DEVELOPMENT; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ANTIBODY SPECIFICITY; BACTERIAL INFECTIONS; CLINICAL TRIALS; COMMERCE; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; FINANCING, GOVERNMENT; IMMUNOGLOBULINS, INTRAVENOUS; METHICILLIN RESISTANCE; RESEARCH SUPPORT; STAPHYLOCOCCUS AUREUS;

EID: 33845706771     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1206-1521     Document Type: Review

References (2)

1. Moore, A. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Reports 4, 114-117 (2003).
2. Mygind, P.H. et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975-980 (2005).